Miyamoto K, Khosrof S, Bursell S E, Rohan R, Murata T, Clermont A C, Aiello L P, Ogura Y, Adamis A P
Laboratory for Surgical Research, Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10836-41. doi: 10.1073/pnas.96.19.10836.
Diabetic retinopathy is a leading cause of adult vision loss and blindness. Much of the retinal damage that characterizes the disease results from retinal vascular leakage and nonperfusion. This study shows that diabetic retinal vascular leakage and nonperfusion are temporally and spatially associated with retinal leukocyte stasis (leukostasis) in the rat model of streptozotocin-induced diabetes. Retinal leukostasis increases within days of developing diabetes and correlates with the increased expression of retinal intercellular adhesion molecule-1 (ICAM-1). ICAM-1 blockade with a mAb prevents diabetic retinal leukostasis and vascular leakage by 48.5% and 85.6%, respectively. These data identify the causal role of leukocytes in the pathogenesis of diabetic retinopathy and establish the potential utility of ICAM-1 inhibition as a therapeutic strategy for the prevention of diabetic retinopathy.
糖尿病视网膜病变是成人视力丧失和失明的主要原因。该疾病的主要特征性视网膜损伤多源于视网膜血管渗漏和无灌注。本研究表明,在链脲佐菌素诱导的糖尿病大鼠模型中,糖尿病视网膜血管渗漏和无灌注在时间和空间上与视网膜白细胞淤滞(白细胞停滞)相关。糖尿病发病数天内视网膜白细胞停滞增加,并与视网膜细胞间黏附分子-1(ICAM-1)表达增加相关。用单克隆抗体阻断ICAM-1可分别使糖尿病视网膜白细胞停滞和血管渗漏减少48.5%和85.6%。这些数据确定了白细胞在糖尿病视网膜病变发病机制中的因果作用,并确立了抑制ICAM-1作为预防糖尿病视网膜病变治疗策略的潜在效用。